Progress in Diagnosis and Management of Scleroderma Lung Disease
Watch John Varga, MD speak at the Scleroderma Patient Education Conference on October 10, 2015. The video highlights important details about current treatments,…
gcscleroderma.wordpress.com
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
rheumnow.com
There are not many proven therapies for Scleroderma Lung; probably just 2. Cyclophosphamide is the mainstay, but its toxicity means alternatives are preferred. Hence Mycophenolate.
Comparing the 2, they appear to be equally effective for staunching lung deterioration, but Cyclophosphamide seems better for the skin and for improving physical functioning, and costs a lot less; but is less well tolerated, causing more deaths than Mycophenolate.
And treatment needs to be maintained longterm. So, count your cost and choose your poison, carefully.
Comparing the 2, they appear to be equally effective for staunching lung deterioration, but Cyclophosphamide seems better for the skin and for improving physical functioning, and costs a lot less; but is less well tolerated, causing more deaths than Mycophenolate.
And treatment needs to be maintained longterm. So, count your cost and choose your poison, carefully.
Netrin-1 May Promote Lung Fibrosis in Scleroderma
Mechanisms underlying the pulmonary fibrosis of systemic sclerosis are poorly understood, yet are the…
rheumnow.com
<p>Translating research into clinical practice. Arthritis Research & Therapy is a leading journal in the field of rheumatology and is notable for the breadth and quality of articles on the broad range of rheumatic and musculoskeletal diseases. The…
arthritis-research.biomedcentral.com
Objective Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This study was designed to evaluate the tolerability of the IPF…
m.jrheum.org